Akero Therapeutics's - AKRO market analysis on 27th September 2020

Transaction Date	Recipient	Shares	Type	Price
21st September 2020	Venture Fund Xi, L.P. Atlas	1,608,785	Conversion of derivative	$0.00
21st September 2020	Venture Fund Xi, L.P. Atlas	6,029,726	Conversion of derivative	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	8,000	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	1,187	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	8,000	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	79,216	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	1,187	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	6,901	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	1,177	Other acquisition or disposition	$0.00
17th September 2020	Venture Capital Vi, L.P. Versant	1,177	Other acquisition or disposition	$0.00

Akero Therapeutics

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.

Ticker: AKRO

Sector: Health Technology

Industry: Pharmaceuticals: Major

SEC Central Index Key (CIK): 1744659

Employees: 13

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis